|
rs121913459
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The second-generation BCR-ABL inhibitors nilotinib (Tasigna; Novartis) and dasatinib (Sprycel; Bristol-Myers Squibb) have shown significant activity after imatinib failure in clinical trials, but still face similar obstacles to imatinib, including negligible activity against the frequent BCR-ABL T315I mutation and modest effects in advanced phases of CML.
|
17853901 |
2007 |
|
rs121913459
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The results of 12 serial samples from 2 patients (case A: Philadelphia-positive acute lymphoblastic leukemia and case B: CML) with the T315I mutant clone were compared with those of direct sequencing or 2 kinds of allele-specific oligonucleotide (ASO)-PCR.
|
21867983 |
2011 |
|
rs121913459
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Ultra-deep sequencing leads to earlier and more sensitive detection of the tyrosine kinase inhibitor resistance mutation T315I in chronic myeloid leukemia.
|
27102501 |
2016 |
|
rs121913459
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Here, we report the hematological, cytogenetic, and molecular response of a patient with refractory CML in chronic phase with e19a2 transcripts, carrying T315I mutation that was successfully treated with ponatinib.
|
24766374 |
2015 |
|
rs121913459
|
|
|
0.800 |
GeneticVariation |
BEFREE |
In chronic myeloid leukemia (CML), resistance against second-generation tyrosine kinase inhibitors (TKI) remains a serious clinical challenge, especially in the context of multi-resistant BCR-ABL1 mutants, such as T315I.
|
30711891 |
2019 |
|
rs121913459
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The described test is useful for detection and relative quantification of the T315I point mutation in chronic myelogenous leukaemia in a sensitive, specific and reproducible manner.
|
21486895 |
2011 |
|
rs121913459
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Here we studied mechanisms of acquired resistance of chronic myeloid leukemia (CML) to tyrosine kinase inhibitors (TKIs) by examining genome-wide gene expression changes in KCL-22 CML cells versus their resistant KCL-22M cells that acquire T315I BCR-ABL mutation following TKI exposure.
|
24967705 |
2014 |
|
rs121913459
|
|
|
0.800 |
GeneticVariation |
BEFREE |
BMS-214662 was cytotoxic against CML blast crisis stem/progenitor cells, particularly in combination with a tyrosine kinase inhibitor and equally effective in cell lines harboring wild-type vs mutant BCR-ABL, including the T315I mutation.
|
18156496 |
2008 |
|
rs121913459
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Ponatinib is approved for the treatment of adults with T315I-positive chronic-, accelerated- or blast-phase chronic myeloid leukaemia (CML), or Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukaemia (ALL) [in the EU and the USA], as well as those with chronic-, accelerated- or blast-phase CML, or Ph+ ALL who are resistant or intolerant to prior tyrosine kinase inhibitor therapy (EU) or for whom no other tyrosine kinase inhibitor therapy is indicated (USA).
|
24807266 |
2014 |
|
rs121913459
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The aim of this study was to evaluate the behavior of T315I mutated cells and to study the presence of potential additional mutations in progenitors and stem cells from a patient with CML.
|
20929330 |
2010 |
|
rs121913459
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Taken together, our data demonstrate that the small molecule AurA inhibitor AKI603 may be used to overcome drug resistance induced by BCR-ABL-T315I mutation in CML.
|
27824120 |
2016 |
|
rs121913459
|
|
|
0.800 |
GeneticVariation |
BEFREE |
A new rapid and sensitive assay for detecting the T315I BCR-ABL kinase domain mutation in chronic myeloid leukaemia.
|
18587017 |
2008 |
|
rs121913459
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Most remarkably, ATO/IFN significantly prolonged the survival of primary T315I-CML mice and displayed a dramatic impairment of disease engraftment in secondary mice, which reflected decreased LIC activity.
|
31034603 |
2019 |
|
rs121913459
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Discovery of (E)-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thio)propanamide (CHMFL-ABL-121) as a highly potent ABL kinase inhibitor capable of overcoming a variety of ABL mutants including T315I for chronic myeloid leukemia.
|
30317026 |
2018 |
|
rs121913459
|
|
|
0.800 |
GeneticVariation |
BEFREE |
HQP1351, an orally bioavailable multikinase BCR-ABL inhibitor, is currently in clinical trials for the treatment of T315I mutant chronic myelogenous leukemia (CML), but the potential application in imatinib-resistant GISTs carrying secondary KIT mutations has not been explored.
|
31673329 |
2019 |
|
rs121913459
|
|
|
0.800 |
GeneticVariation |
BEFREE |
AHI1 gene expression levels and BCR-ABL1 T315I mutations in chronic myeloid leukemia patients.
|
22183070 |
2011 |
|
rs121913459
|
|
|
0.800 |
GeneticVariation |
BEFREE |
We assessed ponatinib for nine patients with recurrent Ph+ CNSL and a T315I mutation after allo-HSCT, including five patients with Ph+ acute lymphoblastic leukemia and four with chronic myelogenous leukemia.
|
31785158 |
2019 |
|
rs121913459
|
|
|
0.800 |
GeneticVariation |
BEFREE |
These results unravel a new molecular target of Btz, that is the Rb pathway, and open new possibilities in the treatment of CML especially for patients that become resistant to IM because of the presence of the T315I mutation.
|
20305692 |
2010 |
|
rs121913459
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Second generation TKIs dasatinib and nilotinib have shown promising results in imatinibresistant or intolerant CML patients, but are not active against CML clones with highly resistant T315I mutation.
|
22483154 |
2012 |
|
rs121913459
|
|
|
0.800 |
GeneticVariation |
BEFREE |
SHC004-221A1, a novel tyrosine kinase, potently inhibits T315I mutant BCR-ABL in chronic myeloid leukemia.
|
28595903 |
2017 |
|
rs121913459
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Interestingly, this substitution is a homologue to the T315I mutation already reported in CML, where it is responsible for acquired resistance to imatinib.
|
15236194 |
2004 |
|
rs121913459
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Expanded distribution of the T315I mutation among hematopoietic stem cells and progenitors in a chronic myeloid leukemia patient during imatinib treatment.
|
20963643 |
2010 |
|
rs121913459
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The third-generation tyrosine kinase inhibitor (TKI) ponatinib shows activity against all common BCR-ABL1 single mutants, including the highly resistant BCR-ABL1-T315I mutant, improving outcome for patients with refractory chronic myeloid leukemia (CML).
|
26773037 |
2016 |
|
rs121913459
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Assessment and follow-up of the proportion of T315I mutant BCR-ABL transcripts can guide appropriate therapeutic decision making in CML patients.
|
16038734 |
2005 |
|
rs121913459
|
|
|
0.800 |
GeneticVariation |
BEFREE |
In this study, we show that human homolog double minute 2 (HDM2) inhibition, with MI-219-a novel compound, and consequently p53 stabilization induce chronic myeloid leukemia (CML) blast crisis cells to undergo apoptosis regardless of the presence of the T315I mutation in the BCR-ABL kinase domain.
|
21350558 |
2011 |